CervoMed shares surge 14.79% after-hours as positive Phase 2b dementia drug trial results pave way for 2026 Phase 3 trial.

CervoMed Inc. surged 14.79% in after-hours trading following the release of positive Phase 2b trial results for its dementia with Lewy bodies (DLB) candidate neflamapimod. The drug demonstrated a 52% reduction in clinical worsening on the CDR-SB primary endpoint at 16 weeks and a 65% reduction at 32 weeks, with durable effects observed in patients without Alzheimer’s co-pathology. Neflamapimod also reduced biomarkers like GFAP, indicating it may address neuroinflammation and synaptic dysfunction underlying DLB. The results, presented at the CTAD conference, bolster the company’s plans to initiate a Phase 3 trial in mid-2026. The drug’s favorable safety profile and consistent clinical improvements across measures reinforced investor confidence in its potential as a first-line DLB treatment.